Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects.

Tomefa E AsempaJoseph L KutiJeffrey C NascimentoSamuel J PopeEdward L SalernoPatrick J TroyYasmeen Abouelhassan

Published in: The Journal of antimicrobial chemotherapy (2023)

The observed bronchopulmonary exposures of taniborbactam and cefepime can be employed to design optimal dosing regimens for clinical trials in patients with pneumonia.

Keyphrases

clinical trial
air pollution
childhood cancer
randomized controlled trial
community acquired pneumonia
young adults
respiratory failure
study protocol